A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT05585320. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT05585320
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Immuneering Corporation
- Industry
- Enrollment
- 209 participants
Conditions and interventions
Conditions
Interventions
- IMM-1-104 + dabrafenib (Treatment Group D) Drug
- IMM-1-104 + modified FOLFIRINOX (Treatment Group C) Drug
- IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) Drug
- IMM-1-104 + pembrolizumab (Treatment Group E) Drug
- IMM-1-104 Monotherapy (Treatment Group A) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 30, 2022
- Primary completion
- May 31, 2026
- Completion
- May 31, 2027
- Last update posted
- Sep 1, 2025
2022 – 2027
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| City of Hope | Duarte | California | 91010 | — |
| University of California San Diego | San Diego | California | 92037 | — |
| Sarcoma Oncology Center | Santa Monica | California | 90403 | — |
| Sarah Cannon Research Institute | Denver | Colorado | 80218 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Florida Cancer Specialists and Research Institute | Lake Mary | Florida | 32746 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Hematology Oncology Associates of Central New York | East Syracuse | New York | 13057 | — |
| Weill Cornell Medicine | New York | New York | 10021 | — |
| Levine Cancer Center | Charlotte | North Carolina | 28204 | — |
| Duke University Cancer Institute | Durham | North Carolina | 27710 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 27203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
| NEXT Oncology | Fairfax | Virginia | 22031 | — |
| University of Wisconsin Clinical Science Center | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05585320, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 1, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05585320 live on ClinicalTrials.gov.